Cover Image
市場調查報告書

大腸激躁症 (IBS):全球醫藥品預測、市場分析

PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 619855
出版日期 內容資訊 英文 185 Pages
訂單完成後即時交付
價格
Back to Top
大腸激躁症 (IBS):全球醫藥品預測、市場分析 PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年12月20日 內容資訊: 英文 185 Pages
簡介

本報告提供大腸激躁症 (IBS)的上市藥及後期階段的開發平台候補藥的相關調查,IBS概要,市場收益,目前治療選項、未滿足需求、機會,主要7個市場的處方藥的銷售額的影響的要素,開發平台分析,現在、未來的處方藥市場上競爭趨勢,市場主要促進因素、阻礙因素、課題等彙整資料。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理學
  • 分類、病期分類系統
  • 症狀
  • 預後
  • QOL

第5章 流行病學

  • 疾病的背景
  • 風險要素、合併症
  • 全球、過去趨勢
  • 預測手法
  • IBS的流行病學的預測
  • 討論

第6章 疾病管理

  • 診斷概要
  • 治療概要
  • 美國
  • EU5個國家
  • 日本

第7章 競爭評估

  • 概要
  • 產品簡介:領導品牌,IBS-C治療藥
  • 產品簡介:領導品牌,IBS-D治療藥
  • 產品簡介:全IBS亞型的治療藥
  • 其他小規模的治療等級

第8章 未滿足需求、機會分析

  • 概要
  • 被IBS處方的有效的處方藥
  • IBS-D患者的新的治療藥
  • IBS-M患者特別核準的醫藥品
  • 與IBS相關的腹痛、膨脹感對應的治療藥
  • 恰當的IBS臨床亞型的正確的診斷

第9章 開發平台評估

第10章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介

第11章 市場展望

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

目錄
Product Code: GDHC150PIDR

Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. IBS is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least three months. IBS is classified into three main subtypes, according to the predominant bowel habit: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed-presentation (IBS-M) IBS.

The IBS treatment landscape remains largely underserved, and ample opportunity exists for pharmaceutical companies to address the numerous unmet needs in this therapy area. Based on insights gathered from primary and secondary research, GlobalData anticipates that two of the new drugs, tenapanor and SYN-010, will have an initial slow uptake, as opposed to Trulance (plecanatide), which has a similar mode of action (MOA) to that of Linzess/Constella (linaclotide). The sales are expected to grow steadily over the forecast period, primarily due to the increased prevalent population and the launch of novel agents to treat IBS-C.

This model covers the market forecast for IBS marketed therapies and late-stage pipeline candidates. The base year of this model is 2016 and the forecast period is 2017-2026.

Scope

  • Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline market revenue from 2016-2026 for IBS. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting prescription drug sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global prescription drug market for IBS. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prescription drug market for IBS.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the prescription drug market for IBS in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 9

2 Executive Summary 10

  • 2.1 The IBS Market Expected to Experience Solid Growth from 2016-2026 11
  • 2.2 Companies Leverage Partnerships to Successfully Develop and Commercialize IBS Products 12
  • 2.3 The IBS Market is Characterized by Significant Unmet Needs 14
  • 2.4 Products With Improved Efficacy Will Have Significant Opportunities in the IBS Market 14
  • 2.5 The Potential Introduction of Late-Stage Pipeline Products Will Drive Growth in the IBS Market 14
  • 2.6 What Do Physicians Think 15

3 Introduction 18

  • 3.1 Catalyst 18
  • 3.2 Related Reports 19
  • 3.3 Upcoming Related Reports 19

4 Disease Overview 20

  • 4.1 Etiology and Pathophysiology 20
    • 4.1.1 Etiology 20
    • 4.1.2 Pathophysiology 21
  • 4.2 Classification or Staging Systems 26
  • 4.3 Symptoms 27
  • 4.4 Prognosis 27
  • 4.5 Quality of Life 28

5 Epidemiology 29

  • 5.1 Disease Background 29
  • 5.2 Risk Factors and Comorbidities 30
  • 5.3 Global and Historical Trends 31
    • 5.3.1 US 33
    • 5.3.2 5EU 34
    • 5.3.3 Japan 35
  • 5.4 Forecast Methodology 35
    • 5.4.1 Sources 36
    • 5.4.2 Forecast Assumptions and Methods 40
  • 5.5 Epidemiological Forecast for IBS (2016-2026) 46
    • 5.5.1 Total Prevalent Cases of IBS 46
    • 5.5.2 Diagnosed Prevalent Cases of IBS 47
    • 5.5.3 Age-Specific Diagnosed Prevalent Cases of IBS 48
    • 5.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS 49
    • 5.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtype 50
    • 5.5.6 Diagnosed Prevalent Cases of IBS Clinical Subtype by Comorbidity 51
  • 5.6 Discussion 52
    • 5.6.1 Epidemiological Forecast Insight 52
    • 5.6.2 Limitations of the Analysis 54
    • 5.6.3 Strengths of the Analysis 55

6 Disease Management 56

  • 6.1 Diagnosis Overview 56
  • 6.2 Treatment Overview 58
    • 6.2.1 Treatment Guidelines 58
    • 6.2.2 Clinical Practice 58
  • 6.3 US 62
  • 6.4 5EU 64
  • 6.5 Japan 65

7 Competitive Assessment 68

  • 7.1 Overview 68
  • 7.2 Product Profiles - Major Brands, IBS-C Therapy 70
    • 7.2.1 Linzess (linaclotide) 70
    • 7.2.2 Amitiza (lubiprostone) 74
  • 7.3 Product Profiles - Major Brands, IBS-D Therapy 77
    • 7.3.1 Xifaxan (rifaximin) 77
    • 7.3.2 Viberzi (eluxadoline) 84
    • 7.3.3 Lotronex (alosetron) 89
    • 7.3.4 Irribow (ramosetron) 92
  • 7.4 Product Profiles - Therapeutic Agents for All IBS Clinical Subtypes 95
    • 7.4.1 Antidepressants 95
  • 7.5 Other Minor Therapeutic Classes 97
    • 7.5.1 OTCs and Non-pharmacological Treatment Options for IBS 97
    • 7.5.2 Off-Label Prescription Treatment Alternatives for IBS 99

8 Unmet Needs and Opportunity Analysis 101

  • 8.1 Overview 101
  • 8.2 More Efficacious Prescription Drugs Indicated for IBS 102
    • 8.2.1 Unmet Need 102
    • 8.2.2 Gap Analysis 103
    • 8.2.3 Opportunity 104
  • 8.3 Novel Therapies for IBS-D Patients 104
    • 8.3.1 Unmet Need 104
    • 8.3.2 Gap Analysis 105
    • 8.3.3 Opportunity 105
  • 8.4 Drugs Specifically Approved for IBS-M Patients 105
    • 8.4.1 Unmet Need 105
    • 8.4.2 Gap Analysis 106
    • 8.4.3 Opportunity 106
  • 8.5 Therapies to Address Abdominal Pain and Bloating Associated with IBS 106
    • 8.5.1 Unmet Need 106
    • 8.5.2 Gap Analysis 107
    • 8.5.3 Opportunity 107
  • 8.6 More Accurate Diagnosis of Appropriate IBS Clinical Subtype 108
    • 8.6.1 Unmet Need 108
    • 8.6.2 Gap Analysis 109
    • 8.6.3 Opportunity 109

9 Pipeline Assessment 110

  • 9.1 Overview 110
  • 9.2 Promising Drugs in Clinical Development 111
    • 9.2.1 Trulance (plecanatide) 112
    • 9.2.2 Tenapanor 117
    • 9.2.3 SYN-010 (oral modified-release lovastatin lactone) 122
  • 9.3 Other Drugs in Development 125

10 Current and Future Players 127

  • 10.1 Overview 127
  • 10.2 Trends in Corporate Strategy 128
  • 10.3 Company Profiles 129
    • 10.3.1 Allergan 129
    • 10.3.2 Astellas 130
    • 10.3.3 Ironwood Pharmaceuticals 131
    • 10.3.4 Takeda 132
    • 10.3.5 Sucampo 133
    • 10.3.6 Sebela Pharmaceuticals 134
    • 10.3.7 Salix 134
    • 10.3.8 Synergy 135
    • 10.3.9 Ardelyx 136
    • 10.3.10 Synthetic Biologics 136

11 Market Outlook 138

  • 11.1 Global Markets 138
    • 11.1.1 Forecast 138
    • 11.1.2 Drivers and Barriers - Global Issues 140
  • 11.2 US 141
    • 11.2.1 Forecast 141
    • 11.2.2 Key Events 143
    • 11.2.3 Drivers and Barriers 143
  • 11.3 5EU 144
    • 11.3.1 Forecast 144
    • 11.3.2 Key Events 146
    • 11.3.3 Drivers and Barriers 146
  • 11.4 Japan 147
    • 11.4.1 Forecast 147
    • 11.4.2 Key Events 149
    • 11.4.3 Drivers and Barriers 149

12 Appendix 151

  • 12.1 Bibliography 151
  • 12.2 Abbreviations 165
  • 12.3 Methodology 168
    • 12.3.1 Forecasting Methodology 168
    • 12.3.2 Diagnosed Patients 168
    • 12.3.3 Percent Drug-Treated Patients 169
    • 12.3.4 Drugs Included In Each Therapeutic Class 169
    • 12.3.5 Launch and Patent Expiry Dates 170
    • 12.3.6 General Pricing Assumptions 171
    • 12.3.7 Individual Drug Assumptions 172
    • 12.3.8 Generic Erosion 174
    • 12.3.9 Pricing of Pipeline Agents 175
  • 12.4 Primary Research - KOLs Interviewed for this Report 176
  • 12.5 Primary Research - Prescriber Survey 180
  • 12.6 About the Authors 181
    • 12.6.1 Analyst 181
    • 12.6.2 Therapy Area Directors 181
    • 12.6.3 Epidemiologists 182
    • 12.6.4 Global Director of Therapy Analysis and Epidemiology 182
    • 12.6.5 Global Head and EVP of Healthcare Operations and Strategy 183
  • 12.7 About GlobalData 184
  • 12.8 Contact Us 184
  • 12.9 Disclaimer 185

List of Tables

  • Table 1: Irritable Bowel Syndrome (IBS): Key Metrics in Seven Major Pharmaceutical Markets 10
  • Table 2: Symptoms of IBS 27
  • Table 3: Risk Factors and Comorbidities for IBS 30
  • Table 4: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 32
  • Table 5: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 47
  • Table 6: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 48
  • Table 7: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages ≥18 Years, N, 2016 51
  • Table 8: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages ≥18 Years, N, 2016 52
  • Table 9: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS 57
  • Table 10: Treatment Guidelines for IBS 58
  • Table 11: Country Profile - US 63
  • Table 12: Country Profile - 5EU 65
  • Table 13: Country Profile - Japan 67
  • Table 14: Leading Treatments for IBS, 2017 69
  • Table 15: Product Profile - Linzess 71
  • Table 16: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks 71
  • Table 17: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks 72
  • Table 18: Safety of Linzess - Most Frequently Reported AEs 73
  • Table 19: Linzess SWOT Analysis, 2017 73
  • Table 20: Product Profile - Amitiza 75
  • Table 21: Safety of Amitiza - Most Frequently Reported AEs 76
  • Table 22: Amitiza SWOT Analysis, 2017 76
  • Table 23: Product Profile - Xifaxan 78
  • Table 24: Efficacy Analysis of Xifaxan in Target 1 and 2 Trials 79
  • Table 25: Efficacy Responder Rates in Target 3 Trial in a Given Week for at Least 2 Weeks During Weeks 3 to 6 of the Double-Blind, First Repeat Treatment Phase 80
  • Table 26: Safety Analysis of Xifaxan in Target 1 and 2 Trials 81
  • Table 27: Safety Analysis of Xifaxan in Target 3 Trial 82
  • Table 28: Xifaxan SWOT Analysis, 2017 83
  • Table 29: Product Profile - Viberzi 85
  • Table 30: Efficacy Analysis of Viberzi in IBS-3001 and IBS-3002 Trials 86
  • Table 31: Common AEs of Viberzi 87
  • Table 32: Viberzi SWOT Analysis, 2017 88
  • Table 33: Product Profile - Lotronex 90
  • Table 34: Safety of Lotronex - Most Frequently Reported AEs 91
  • Table 35: Lotronex SWOT Analysis, 2017 92
  • Table 36: Product Profile - Irribow 93
  • Table 37: Irribow SWOT Analysis, 2017 95
  • Table 38: Antidepressants in IBS, SWOT Analysis, 2017 97
  • Table 39: Summary of Minor Therapeutic Classes, 2016 98
  • Table 40: Mechanisms of Action and AEs of Minor Therapeutic Classes, 2016 99
  • Table 41: Product Profile - Trulance 113
  • Table 42: Trulance SWOT Analysis, 2017 116
  • Table 43: Product Profile - Tenapanor 117
  • Table 44: T3MPO-1 Trial-Tenapanor 6 of 12 Week Treatment Results 118
  • Table 45: T3MPO-2 Trial-Tenapanor 6 of 12 Week Treatment Results 119
  • Table 46: Tenapanor SWOT Analysis, 2017 121
  • Table 47: Product Profile - SYN-010 122
  • Table 48: SYN-010 SWOT Analysis, 2017 125
  • Table 49: Other Drugs in Development for IBS, 2017 126
  • Table 50: Key Companies in the IBS Market in the 7MM, 2017 127
  • Table 51: Allergan's IBS Portfolio Assessment, 2017 130
  • Table 52: Astellas' IBS Portfolio Assessment, 2017 131
  • Table 53: Ironwood's IBS Portfolio Assessment, 2017 132
  • Table 54: Takeda's IBS Portfolio Assessment, 2017 133
  • Table 55: Sucampo's IBS Portfolio Assessment, 2017 134
  • Table 56: Prometheus/Sebela Ireland's IBS Portfolio Assessment, 2017 134
  • Table 57: Salix's IBS Portfolio Assessment, 2017 135
  • Table 58: Synergy's IBS Portfolio Assessment, 2017 136
  • Table 59: Ardelyx's IBS Portfolio Assessment, 2017 136
  • Table 60: Synthetic Biologics' IBS Portfolio Assessment, 2017 137
  • Table 61: IBS - Global Drivers and Barriers, 2016-2026 141
  • Table 62: Key Events Impacting Sales for IBS in the US, 2016-2026 143
  • Table 63: IBS - US Drivers and Barriers, 2016-2026 144
  • Table 64: Key Events Impacting Sales for IBS in the 5EU, 2016-2026 146
  • Table 65: IBS - 5EU Drivers and Barriers, 2016-2026 147
  • Table 66: Key Events Impacting Sales for IBS in Japan, 2016-2026 149
  • Table 67: IBS - Japan Drivers and Barriers, 2016-2026 150
  • Table 68: Key Historical and Projected Launch Dates for IBS 170
  • Table 69: Key Patent Expiry Dates for IBS 170
  • Table 70: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 180

List of Figures

  • Figure 1: Global (7MM) Sales for IBS by Region, 2016 and 2026 12
  • Figure 2: Analysis of the Company Portfolio Gap in IBS During the Forecast Period 13
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Products Under Development for IBS 15
  • Figure 4: IBS Pathophysiology 21
  • Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages ≥18 Years, 2016 33
  • Figure 6: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS 36
  • Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS 37
  • Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS Clinical Subtypes 38
  • Figure 9: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS With Comorbidity 39
  • Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 49
  • Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 50
  • Figure 12: Unmet Need and Opportunity in IBS, 2017 102
  • Figure 13: Bullseye Diagram of Products in Clinical Development for IBS, 2017 110
  • Figure 14: Key Phase II/III Trials for Promising Pipeline Agents for IBS, 7MM, 2016-2026 111
  • Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of IBS in the Forecast Period 112
  • Figure 16: Clinical and Commercial Positioning of Trulance 115
  • Figure 17: Clinical and Commercial Positioning of Tenapanor 120
  • Figure 18: Clinical and Commercial Positioning of SYN-010 124
  • Figure 19: Analysis of the Company Portfolio Gap in IBS During the Forecast Period 128
  • Figure 20: Global (7MM) Sales for IBS by Region, 2016 and 2026 139
  • Figure 21: Global (7MM) Sales for IBS by Drug, 2016 and 2026 140
  • Figure 22: Sales for IBS in the US, 2016 and 2026 142
  • Figure 23: Sales for IBS in the US by clinical subtype, 2016-2026 143
  • Figure 24: Sales for IBS in the 5EU, 2016 and 2026 145
  • Figure 25: Sales for IBS in the 5EU by clinical subtype, 2016-2026 146
  • Figure 26: Sales for IBS in Japan, 2016 and 2026 148
  • Figure 27: Sales for IBS in Japan by clinical subtype, 2016-2026 149
Back to Top